Good morning, and thank you for standing by. All participants are currently in listen-only mode. Following management's prepared remarks, we will open the call for question-and-answer session. Please be advised that today's conference call is being recorded. I would now like to turn the conference call over to Sarah Verrin. Please go ahead.
Before we begin, I will take a moment to read the forward-looking statements disclaimer. This call and the question-and-answer session that follows contain forward-looking statements within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Words such as expect, anticipate, intend, plan, believe, seek, estimate, and similar expressions are intended to identify forward-looking statements. These statements include, among other things, the company's expectations regarding continued revenue growth, commercial expansion, physician adoption and utilization of ProSense, expansion of its U.S. commercial organization and international presence, investing in the company's commercial, clinical, and organizational capabilities, the progress and potential impact of the ChoICE post-marketing study, future clinical evidence generation, intellectual property protection, and the company's long-term market opportunity. Forward-looking statements are subject to risks and uncertainties, many of which are beyond the company's control.
These risks are described in greater detail in the risk factor section of the company's annual report on Form 20-F for the year ended December 31st, 2025, filed with the SEC on March 17th, 2026, and in other documents filed with or furnished to the SEC. The company undertakes no obligation to update or revise any forward-looking statements, except as required by law. This conference call contains time-sensitive information and speaks only as of today's live broadcast, November 18th, 2026. I will now turn the call over to IceCure Medical's CEO, Eyal Shamir. Eyal, please go ahead.
Thank you, operator, and thank you everyone for joining us today. The first nine months of 2026 demonstrated continued commercial momentum for ProSense, particularly in the United States, our primary commercial market. Total revenue increased 26% year-over-year, while U.S. sales increased 83%, reflecting the continued expansion of our commercial activities and growing adoption of ProSense. During the third quarter, we also continued to expand our U.S. commercial presence, advance the ChoICE post-marketing study, and strengthen the clinical evidence supporting cryoablation. We believe these developments demonstrate the progress we are making in translating the clinical and regulatory foundation we have built over the past several years into commercial growth and broader physician adoption. Let me start with our financial and commercial performance in the United States.
By the end of the third quarter of 2026, we nearly doubled our U.S. commercial footprint, growing from 11 states to the end of the second quarter of 2025 to 21 states. We added dedicated sales and marketing professionals in key regions, including New York, Southern California, the Midwest, and Florida, as well as additional clinical support personnel. This expanded commercial infrastructure enabled us to engage with more physicians and medical institutions, provide clinical support and training, and support the adoption of utilization of ProSense. We believe the combination of broader geographic coverage, the expanded commercial team, and increased physician engagement provide a stronger foundation for our continued U.S. commercial growth. Another important area of progress is our ChoICE post-marketing study, which we designed to generate additional clinical evidence while expanding physician experience with ProSense.
Since initiating the study, we have now established three clinical sites, including West Cancer Center in Germantown, Tennessee, Adventist Health Glendale in Glendale, California, and Legacy Health in Portland, Oregon, and have begun enrolling and treating patients at participating U.S. centers. We progressed from activating our first clinical site to enrolling and treating the first patients at West Cancer Center in Tennessee, and have since announced initial patients enrolled at two participating U.S. clinical sites. We are also engaging with additional leading medical centers regarding potential participation in the study. We view ChoICE as closely connected to our broader commercial strategy. As additional leading institutions and physicians gain clinical experience with ProSense, the study can generate real-world evidence, support physician confidence, and contribute to a broader adoption over time.
Beyond our commercial and clinical progress in the United States, we continue to expand the regulatory and commercial footprint of ProSense internationally. Recent development includes regulatory approval in China and an exclusive distribution agreement in the Netherlands, further expanding the market in which ProSense can be commercialized. We also seeing continued interest in physician and medical institution in Europe, South America, and other international markets as we work to build the regulatory and commercial relationships needed to support broader adoption of ProSense. At the same time, we continue to build out the scientific foundation supporting cryoablation. During the third quarter, we highlighted two additional peer-reviewed scientific publications addressing the role of cryoablation in breast cancer treatment de-escalation, including research relating to early-stage breast cancer and axillary lymph node metastasis.
We believe the continued generation of independent scientific evidence can further support physician awareness and confidence in cryoablation and contribute to broader adoption over time. In parallel, we continue to strengthen our intellectual property portfolio as ProSense expands into additional markets and gain broader commercial exposure. We consider our IP an important strategic asset and remain focused on protecting the technology's underlying process as we pursue broader commercial adoption globally. Taking together, this development reflects the progress we are making across our commercial, clinical, and international activities. Our focus remains executing, expanding our commercial presence, increasing physician adoption and utilization of ProSense, advancing our clinical program, and building the evidence needed to support broader adoption. While we are still in early stage of realizing the commercial opportunity for ProSense, we believe the progress we are seeing, particularly in the United States, provide a stronger foundation for continued growth.
With that, I will turn the call over to our Chief Financial Officer, Meir Peleg, who will review our financial results in greater details.
Thank you, Eyal, and good morning, everyone. I will briefly review our financial results for the nine-month end in September 30, 2026. Total revenues for the first nine months of 2026 increased approximately 26% to $2.6 million compared to $2.1 million in the corresponding period of 2025. Gross profit increased approximately 22% to $762,000 compared to $626,000 in the prior year period. As Eyal mentioned, we are particularly pleased with the growth in the U.S., where sales increased 83% year-over-year during the first nine months of the year. This performance reflects the continued expansion of our commercial activities and the growing market presence of ProSense. Regarding operating expenses, research and development expenses were approximately $6.5 million compared to $5.1 million in the corresponding period last year. The increase primarily reflects higher expenses related to the ChoICE post-marketing study and other clinical and development activities.
Sales and marketing expenses increased approximately 20% to $3.6 million compared to $3 million in the prior year period, primarily reflecting the continued expansion of our U.S. commercial activities, while U.S. sales grew 83% over the same period. General and administrative expenses were approximately $3.5 million compared to $3.3 million in the corresponding period of 2025. Operating loss for the first nine months of 2026 was approximately $12.9 million compared to $10.8 million in the prior year period. Net loss was approximately $12.9 million compared to $10.8 million during the first nine months of 2025. As of September 30, 2026, cash and cash equivalents totaled approximately $8.2 million compared to approximately $8.9 million year-end 2025. We continue to carefully manage our financial resources while investing in the commercial, clinical, and organizational capabilities that we believe are essential to supporting our long-term growth strategy.
Our investment in expanding the U.S. commercial organization and advancing the ChoICE study reflect our commitment to building the infrastructure and clinical evidence needed to support broader adoption of ProSense. With that, I will turn the call back to the operator to open the line for questions.
Thank you. Ladies and gentlemen, at this time, we will begin the question-and-answer session. If you have a question, please press star one. If you wish to cancel your request, please press star two. If you are using speaker equipment, kindly leave the handset before pressing the numbers. Your questions will be pulled in the order they're received. Please stand by while we pull for your questions.
The first question is from Scott Henry of A.G.P. Please go ahead.
Thank you, and good morning or afternoon, depending on location. I guess starting on the revenue side, last year we saw a significant sequential boost in Q4 of the year. Do you think we'll see that this year, or was that kind of a one-time event? Thank you.
Hi, Scott. Meir, please answer that, and if needed, Shad will add to it.
I think maybe Shad will start, and I will add some color for the rest of the world.
Okay. Shad, please go ahead.
Yeah. Thanks for the question. I can speak specifically to the U.S. We feel like we're starting to get some real traction here in the U.S. and also getting some momentum with that. We would expect that our sales revenue would continue to increase quarter-over-quarter. Meir, do you want to talk about the rest of the world?
Yeah. I think we showed, and it's also can be seen in the square that we have some kind of seasonality. Revenue, while Q3 is mostly weaker than the others, together with Q1, Q4 is normally our best. I cannot say it will be the same as last year, maybe even better, but it will be better, we assume, of course, and project it will be better than Q3 2026.
Okay, great. Thank you for that feedback. Without giving guidance on 2027, can you talk about your expectations, how the revenue ramp should continue? It sounds like things are picking up and we should see accelerating revenue growth in 2027. I just wanted to get your thoughts on it. Thank you.
Again, we are not giving guidance, and thank you for the question. It is a good one. We do see acceleration in sales, and the projection for next year for revenue is a healthy double-digit growth. I will say that in this way.
Okay, great. If I could just get one final question. On the ChoICE study, what kind of early feedback are you getting? Are the physicians finding it easy to move up the learning curve? Just any kind of feedback you are getting from the early days. Thank you.
Yeah. Hi, Scott. This is Eyal. I will answer that, and if needed, Shad, our VP Sales for North America, and Shay, our COO, will be able to add. As we announced the first two sites, one of them is running by Dr. Richard Fine, together with some of his colleagues. West Clinic and Dr. Fine, they have very well experience. They participated in the ICE3 study, and they did other cases. Same for Glendale, California, Dr. Dennis Holmes. He is a long user, high-volume user, so they are both experienced. One of the new sites that we announced by Dr. Nathalie Johnson from Portland, Oregon, past president of the society. She is a new user, and she did some cases before at the PMS, and she did the first case for the PMS.
She found it, all the patients and for the new users, very easy to use, excellent, minimally invasive solution. So, extremely satisfied with the cases that she did.
Okay, great. Thank you for taking the questions.
Thank you, Scott.
The next question is from Kemp Dolliver from Brookline Capital Markets. Please go ahead.
Great. Thank you. What is the installed base of consoles in the U.S. now?
As you could see from the revenue growth, as we announced, also new sites. We are not giving guidance. Last time that we discussed the active site was on June. We are still having some orders that we need to ship some orders before the end of the year. I believe that in few weeks or months or two, we will give some update information of that. We definitely see a growth in sales and sites.
Okay, good. To clarify on the ChoICE study, are you currently at five sites?
Yeah. Shad, could you take these questions?
Yes. We're currently at four sites as of today, but we're expecting to finalize some additional sites here in the very near future. We've made some really good progress since the last call in regards to the recruiting process of sites, the contracting with the sites, and also kind of the commercial aspect as well. I think you should kind of expect to see kind of more of a steady cadence of new sites being enrolled into the study over the next couple of months.
Okay, great. The last question is the commercial team. I think as of last month or so ago, it was around seven, and you were thinking it would be nine at the end of the year. Is that still your plan?
Yeah. So, Kemp, as you saw in the earnings release from this morning, recently, actually almost a week ago, we joined an excellent expert to support us in Florida. Extremely important market. Two to three months ago, we had someone in California. Again, excellent and very important market for future growth. We might add another one until the end of the year or very early next year. Next year, we are planning, of course, to grow with the team in order to support the sales growth, as Meir mentioned, with important double-digit growth in the U.S.
Great. Thank you.
Thank you, Kemp.
Thank you.
The next question is from Thomas McGovern from Maxim Group. Please go ahead.
Guys, thanks for taking my question. The first one's just on the ChoICE study. Following the second quarter update, we were anticipating the first patient to be enrolled in September, and we saw the update that they were treated back in October. Just curious, where's that pipeline now, and what's your outlook compared to those deadlines that we've discussed in the past? We were expecting 80 patients by the end of March 2027, and then the 400 by March 2029. Are those deadlines you believe you're on track to hit?
I am not sure that we will be able to do the 400 within the three years, because some of the contracts, agreements, some of the sites is taking them longer time. Early this year, we had some difficulties to travel, but we are joining more and more sites that they have pipeline of patients. Some of them even will join and start to treat patients before the end of the year, and very early next year. But I believe that we will be able to fill the gap. One more site will be on board, and I know that some of them are having even patients that really fit to the trial and waiting to be treated. But at the moment, it is a bit too early to say that if we will be able to meet the 400 exactly three years, or maybe some short time after that, or whatever.
Okay. You guys have some flexibility to go to the FDA and kind of articulate that case and get some extension time there?
Sure. We have continuous communication with the FDA. We are giving them also updates, so we, of course, we will discuss it with them in a mutual way. We would like to see the patients, and they like to see the patients, so I am sure that we will come to a mutual agreement on that.
Okay. Great to hear. All right. On the international side of the business, you guys gave updates on the approvals for both regulatory and IP approvals in China and the Netherlands distributor. I am just curious, how do you guys plan to go to market in China? Are you guys expecting to do a partnership, have a distributor relationship? When can we start to see that revenue come in? The follow-up questions would be on Japan and Canada. Just curious if we can get an update on timelines for approval on that front.
Yeah. Okay. I will start with China. We are now in discussions with some potential partners, mainly more as a mode of distribution. In China, of course, you need to work with them in a close partnership, but it will be more like a distribution. As soon as we're going to have something in place, we will do a proper announcement as needed. We are working on that. Health Canada, we are waiting on the Breast Cancer Canada Health approval, and that could be in the next few weeks. Maybe it will take two to four months. We expect, we answered them all the questions that they had, and we're expecting to get approval in the next few months. In Japan, we expect that Terumo will make the submission to the Japanese FDA, to the PMDA, during the first semester of 2027.
Understood. I appreciate you answering all my questions.
Thank you.
If there are any additional questions, please press star one. There are no further questions at this time. I will turn the call over to Eyal Shamir for concluding remarks, please.
Thank you, everyone, for questions and for joining us today. As we look ahead, our priorities are clear. Accelerating U.S. commercial growth, expand physician adoptions and utilization of ProSense, advance the ChoICE study, and continue building the clinical evidence supporting cry ablation. With U.S. sales up 83% year-over-year during the first nine months of 2026, an extended commercial footprint, and continuous clinical progress, we believe we are building a stronger foundation for the next phase of ProSense commercialization. We remain focused on execution and on translating this progress into broader adoptions and long-term value for our shareholders. Thank you again for your continuous interest and support. We look forward to updating you on our progress.
This concludes the IceCure Medical third quarter and nine months 2026 financial results conference call. Thank you for your participation. You may go ahead and disconnect.